Pear Bio utilizes computer vision to transform patient tumor biopsies into 3D immune-microtumors, enabling side-by-side testing of various treatment options to predict individual responses. This approach addresses the challenge of matching patients with effective therapies for hard-to-treat cancers while also identifying new therapeutic targets from excess tissue.
Funding
$19.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Matching cancer patients with effective therapies, especially for hard-to-treat cancers, remains a significant challenge. Traditional methods often fail to predict individual responses accurately, leading to delays in treatment and suboptimal outcomes. Furthermore, identifying new therapeutic targets from patient tissue is difficult.
Solution
Pear Bio transforms patient tumor biopsies into 3D immune-microtumors, creating a platform for personalized cancer precision medicine. This approach enables side-by-side testing of various treatment options directly on a patient's tumor tissue to predict individual responses. By characterizing excess tissue, Pear Bio also identifies new therapeutic targets and develops novel therapies for patient populations with high unmet needs. Their services aim to match patients with effective therapies and advance cancer treatment options.
Target Audience
Pear Bio's primary customers are cancer patients with hard-to-treat cancers, oncologists seeking personalized treatment options, and pharmaceutical companies interested in drug discovery and development.
Features
- Creation of 3D immune-microtumors from patient tumor biopsies.
- Side-by-side testing of multiple treatment options to predict individual patient responses.
- Advanced multi-omic analysis for target identification and drug discovery.
- Personalized testing services to determine therapies with measurably better anti-tumor activity.
- Development of novel therapies for patient populations with high unmet needs.